This is the RSS news feed of one of our private news channels on LSIS - The Life Science Infromation Service. Please visit us to find a current view of this one and many more channels via our alerting push services: http://www.lsis.com/channels/?query=43 http://www.lsis.com/goto/r43/rss 2012-02-05T11:10:23+01:00 text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 Cytokines are critical in allergic intercellular communication networks, and they contribute to disease pathology through the recruitment and activation of pro-inflammatory leukocytes and in chronic disease to pro-fibrotic/remodeling events. Th2 cytokines predominate primarily in mild to moderate allergic asthma, although clinical trials with inhibitors of IL-4 and IL-5 have not provided the robust efficacy observed in animal models of allergy. These results not only highlight the complexity (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 J Immunotoxicol. |-| Kamperschroer C, Kaur A, Lebrec H. |-| Immunotoxicology Center of Emphasis, Drug Safety Research and Development, Pfizer, Inc. , Eastern Point Road, Groton, CT 06340 , USA. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 Weak peroxisome proliferator-activated receptor (PPAR) ? agonists (fibrates) are used to treat dyslipidemia. This study compared the effects of the potent and selective PPAR? agonist CP-778875 on peroxisomal ?-oxidation and cardiac and/or skeletal muscle injury with those of the weak PPAR? agonist fenofibrate. We hypothesized that these muscle effects are mediated through the PPAR? receptor, leading to increased ?-oxidation and consequent oxidative stress. CP-778875 (5 or 500 mg/kg) and (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 BACKGROUND: As multiple vaccines are administered concomitantly during routine pediatric immunizations, it is important to ascertain the potential interference of any new vaccine on the immune response to the concomitantly administered vaccines. OBJECTIVES: Immune responses to meningococcal serogroup C-tetanus toxoid conjugate vaccine (MnCC-TT) and the diphtheria and tetanus antigens in routine pediatric vaccines (DTaP-HBV-IPV/Hib and DTaP-IPV+Hib) when given concomitantly with PCV13 were (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 Most of us assume that success will lead to happiness. Shawn Achor, founder of the corporate strategy firm Good Think, argues that we've got it backward; in work he's done with KPMG and Pfizer, and studies he's conducted in concert with Yale's psychology department, he has seen how happiness actually precedes success. Happy employees are more productive, more creative, and better at problem solving than their unhappy peers. In this article, Achor lays out three strategies for improving your (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 This study evaluated the efficacy of adjunctive pregabalin versus placebo for treatment of patients with generalized anxiety disorder (GAD) who had not optimally responded to previous or prospective monotherapies. This was a phase 3, randomized, double-blind, placebo-controlled study. Patients diagnosed with GAD who had a historical and current lack of response to pharmacotherapy [Hamilton Anxiety Rating Scale (HAM-A) of ?22 at screening] were randomized to adjunctive treatment with either (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 Human glucokinase (GK) is a principal regulating sensor of plasma glucose levels. Mutations that inactivate GK are linked to diabetes, and ones that activate it are associated with hypoglycemia. Unique kinetic properties equip GK for its regulatory role: although it has weak basal affinity for glucose, positive cooperativity in its binding of glucose causes a rapid increase in catalytic activity when plasma glucose concentrations rise above euglycemic levels. In clinical trials, small (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 The pharmaceutical industry is increasingly using biomarkers in clinical trials in order to determine if new drug candidates are displaying the expected pharmacological properties and to give early indications if they are showing efficacy or unexpected toxicity. This is especially true for the development of new drug candidates for psychiatric disorders such as schizophrenia and depression, where it is imperative to understand whether the drug is reaching the brain and acting on the target. A (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 The highly specific mechanism of action of the selective serotonin re-uptake inhibitors (SSRIs) confers advantages on this group, relative to other classes of antidepressant, and thus represents a significant advance in the pharmacotherapy of depression. Whilst their clinical efficacy is equivalent to that of the tricyclic antidepressants (TCAs), the SSRIs have a greatly reduced risk of toxicity in overdose and have been shown to be significantly better tolerated. Specifically, the SSRIs have (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 J Psychopharmacol. |-| Doogan D. |-| Medical Director Medical Department Pfizer Ltd, Sandwich Kent CT13 9NJ, UK. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 The long-term outlook for patients with unipolar depression is often poor. As few as one-fifth will remain well and a similar number will suffer chronic depression. It is now standard practice to extend acute treatment into a 4-6 month period of continuation therapy, and the value of prophylactic treatment over longer periods is becoming more widely recognised. Care must, however, be exercised in choosing suitable long-term treatment. Relatively little work on the prophylactic efficacy of the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=43 Merck & Co. swung to a fourth-quarter profit from a year-earlier loss that was weighed down by an asset write-down for a drug-research setback, while sales inched up 2%. The Whitehouse Station, N.J., drug maker issued a forecast for full-year 2012 results that leaves room for earnings growth, while sales are expected to be flat or down due to the impending loss of U.S. patent protection for its top-selling drug, the asthma and allergy treatment Singulair. The expected generic competition for (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 Focal Adhesion Kinase (FAK) is a non-receptor kinase that is overexpressed in many types of tumors and plays a key role in cell adhesion, spreading, motility, proliferation, invasion, angiogenesis, and survival. Recently, FAK has been proposed as a target for cancer therapy, and we performed computer modeling and screening of the National Cancer Institute (NCI) small molecule compounds database to target the ATP-binding site of FAK, K454. More than 140,000 small molecule compounds were (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 This review article is a current survey of excipients used in approved injectable products. Information provided includes concentration ranges, function, frequency of use, and role in dosage form. This article is an update of a paper published more than a decade ago (reference 11). Since then many new products have been approved. Safety concerning excipients has evolved as the scientific community continues to learn about their usage. New excipients are being used in early phases of clinical (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 The aim of this study was to evaluate the appropriateness of piperacillin/tazobactam (Tazocin(); Pfizer, New York, NY) usage in our hospital. |-| Infect Drug Resist. |-| Khan FY, Elhiday A, Khudair IF, Yousef H, Omran AH, Alsamman SH, Elhamid M. |-| Department of Medicine, Hamad General Hospital, Doha, Qatar. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 Target-mediated clearance and high antigen load can hamper the efficacy and dosage of many antibodies. We show for the first time that the mouse, cynomolgus and human cross-reactive, antagonistic anti-Proprotein Convertase Substilisin Kexin type 9 (PCSK9) antibodies J10 and the affinity matured and humanized J16 exhibit target-mediated clearance, resulting in dose-dependent pharmacokinetic (PK) profiles. These antibodies prevent the degradation of Low Density Lipoprotein receptor (LDLR) thus (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 The isolated perfused rat liver (IPRL) has been extensively used as an intact organ model for determination of hepatic clearance and metabolism of drugs. The IPRL model can also be applied to determine physiologically based pharmacokinetics. Since the IPRL model avoids neural and hormonal interferences and excludes influences from absorption processes and non-hepatic elimination routes such as renal excretion and respiration, it provides a relatively clean hepatic system to study metabolism (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 Discovery of small molecular inhibitors for treatment of rheumatoid arthritis is a major ongoing effort within the pharmaceutical industry. Spleen tyrosine kinase (SYK) is one of leading small molecular targets with regard to clinical development due to efforts by Rigel and Portola. In this review we provide a comprehensive overview of the SYK patent landscape. The patent literature we evaluated relates to any organization that has filed applications that imply that SYK is the intended (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=43 A treatment for Alzheimer's disease is the drug industry's longest shot, and any brave investors willing to place a bet on the outcome are likely to focus on Eli Lilly & Co. Lilly and Pfizer Inc are the farthest along in developing experimental medicines for the memory-robbing disease. But Lilly, as the far smaller company, has much more upside for its share price if it hits pay dirt. The field is littered with high-profile failures, one of the most recent being a previous Lilly compound. (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=43 SUNNYVALE, Calif., Feb. 2, 2012 (GLOBE NEWSWIRE) - With pharmaceutical companies like Pfizer Inc. investing in shifting operations to a few bioscience hotspots (Wall Street Journal, November 23, 2011), Sunnyvale, CA, in the heart of Silicon Valley, is betting that a testimonial by successful CEO Rene Schena of Arrayit Corporation will seal the deal. Sunnyvale is currently home to Cepheid, Lockheed Martin, Yahoo, Network Appliance, Molecular Devices, Intuitive Surgical, St. Jude Medical, and (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=43 SAN DIEGO-(BUSINESS WIRE)- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - News) announced that results from the Phase II study of its Captisol-enabled, propylene glycol-free (PG-free) Melphalan program were featured this evening in a poster presentation at the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT) in San Diego. The Phase II study was completed in late 2011 (…) text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/channels/?query=43 ScienceDaily (Feb. 1, 2012) New findings, led by neuroscientists at the University of Bristol and recently published in the journal Neurobiology of Aging, reveal a novel mechanism through which the brain may become more reluctant to function as we grow older. See Also: Health & Medicine Nervous System Brain Tumor Healthy Aging Mind & Brain Intelligence Dementia Neuroscience Living Well Reference Sensory neuron Neurobiology Chemical synapse Pupillary reflex It is not fully understood why the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 Sertraline, a novel selective serotonin re-uptake inhibitor, has been proven as effective as amitriptyline and imipramine, and more effective than placebo, in double-blind controlled studies in patients with major depressive disorder. The question 'Do symptoms predict response to treatment?' is an important one in clinical practice. In order to try and answer this question, four double-blind clinical trials in major depressive disorder have been examined for clinically important symptoms and (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 As the societal and economic burdens of Alzheimer's disease (AD) continue to mount, so does the need for therapies that slow the progression of the illness. Beta amyloid has long been recognized as the pathologic hallmark of AD, and the past decade has seen significant progress in the development of various immunotherapeutic approaches targeting beta amyloid. This paper reviews active and passive approaches aimed at beta amyloid, with a focus on clinical trial data. |-| Int J Alzheimers Dis. (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 Depression is common in physically ill populations, although it is frequently unrecognized and untreated. Diagnosis and antidepressant treatment are discussed. The side-effect profiles of the selective 5-HT re-uptake inhibitors suggest they may offer new therapeutic opportunities in physically ill patients. Sertraline may be of particular benefit in some patients due to its distinct pharmacological profile and the potential for fewer drug interactions. Further evaluation is necessary to (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=43 PARIS-(BUSINESS WIRE)-Regulatory News: AB Science SA (Paris:AB) (NYSE Euronext - FR0010557264 - AB) today announced encouraging results from a phase 2 study with its investigational drug, masitinib, in Gleevec-resistant gastrointestinal stromal tumors (GIST). Masitinib significantly improved overall survival in patients with Gleevec-resistant gastrointestinal stromal tumors (GIST) as compared to Sutent (sunitinib) from Pfizer, a drug approved for second-line treatment of GIST, currently the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=43 Nottingham, UK, 01 February, 2012 Exco InTouch, the leading provider of mobile patient engagement and communication solutions for the pharmaceutical and healthcare sectors, announces the appointment of Madhav Vattikuti as Chief Technology Officer (CTO). Vattikuti s role will see him use his significant technology expertise and background to strengthen delivery and development of Exco InTouch s market leading mobile technology into vertical markets such as eClinical, mHealth and Late Phase. (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=43 Pfizer Inc. is recalling 1 million packets of birth control pills because of a packaging error that could leave women with an inadequate dose of the hormone-based drugs and raise the risk that they will get pregnant accidentally. The problem affects 14 lots of Lo/Ovral-28 tablets and 14 lots of generic Norgestrel and Ethinyl Estradiol tablets. Both products are manufactured by Pfizer and marketed in the U.S. by Akrimax Rx Products under the Akrimax Pharmaceuticals brand. Pfizer found that some (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=43 Drug makers Pfizer Inc. and Eli Lilly & Co. were hurt by the "patent cliff," with each reporting declines in fourth-quarter profit due to new generic competition for top-selling drugs. Both companies also spoke cautiously about experimental Alzheimer's disease drugs they're developing separately, though investor enthusiasm has mounted in the off chance that one or both of the drugs will reach the market. Key clinical data for both drugs are due out later this year. Pfizer's profit declined 50% (…) text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/channels/?query=43 ScienceDaily (Jan. 31, 2012) A report from investigators at the Massachusetts General Hospital (MGH) Cancer Center has defined the role of a recently identified gene abnormality in a deadly form of lung cancer. Tumors driven by rearrangements in the ROS1 gene represent 1 to 2 percent of non-small-cell lung cancers (NSCLC), the leading cause of cancer death in the U.S. The researchers show that ROS1-driven tumors can be treated with crizotinib, which also inhibits the growth of tumors driven by (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 The HPA responses to bacterial infection are mediated, in part, by actions of LPS on pituitary folliculostellate (FS) cells which release pro-inflammatory cytokines (e.g. IL-6) and thereby facilitate ACTH release from neighbouring corticotrophs. Here we used two murine pituitary cell lines [TtT/GF (FS cells) and AtT20 D16:16 (corticotrophs)], alone and in co-culture, and an in vivo model of endotoxaemia to examine the potential role of NF?B in mediating LPS-induced ACTH secretion. Both cell (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 Industrial CHO cell fed-batch processes have progressed significantly over the past decade, with recombinant protein titer consistently reaching the gram per liter level. Such improvements have largely resulted from separate advances in process and cell line development. Model-based selection of targets for metabolic engineering in CHO cells is confounded by the dynamic nature of the fed-batch process. In this work, we use a dynamic model of CHO cell metabolism to simultaneously identify both (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 PURPOSE: To evaluate the visual outcomes, choroidal neovascular complex status, and adverse events in patients with visually significant cataract and neovascular age-related macular degeneration (AMD) who had cataract surgery. SETTING: Private practices, Beverly Hills, California, and New London, Connecticut, USA. DESIGN: Case series. METHODS: Data were abstracted from the medical records of patients with neovascular AMD treated by anti-vascular endothelial growth factor (anti-VEGF) therapy (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 Cognitive decline occurs during normal aging and is likely to be reflected in the neurophysiological properties of neural circuits with key roles in cognition, for example those of the limbic system. To identify candidate neurophysiological changes we used patch clamp methods to compare the intrinsic excitability properties of hippocampal CA1 pyramidal neurons of mature adult (8-10 month) and aged (22-24 month) mice. Resting potential, input resistance, and the "sag" observed on injection of (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 BACKGROUND: Although third mandibular molar extraction is a widely used and validated model of acute pain for evaluating analgesic efficacy, a large proportion of patients experience moderate or severe pain following this procedure and require analgesia. Current treatment options have been associated with safety concerns and alternative therapies are sought. OBJECTIVE: Our aim was to assess the efficacy and safety of an additional 200-mg dose of celecoxib, administered 5 to 12 hours after an (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=43 NEW YORK-(BUSINESS WIRE)-Pfizer Inc. (NYSE: PFE): ¢Fourth-Quarter 2011 Revenues of $16.7 Billion; Full-Year 2011 Revenues of $67.4 Billion ¢Fourth-Quarter 2011 Adjusted Diluted EPS(1) of $0.50, Reported Diluted EPS(2) of $0.19; Full-Year 2011 Adjusted Diluted EPS(1) of $2.31, Reported Diluted EPS(2) of $1.27 ¢Achieves Full-Year 2011 Financial Guidance; Updates 2012 Financial Guidance Primarily to Reflect Unfavorable Changes in Foreign Exchange Rates From Mid-October 2011 to Mid-January 2012 text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=43 Pfizer Inc. is preparing to seek U.S. regulatory approval to sell a new menopause drug that could pose an alternative to the company's older hormone-replacement therapies, which have been tied to safety risks. However, repeated delays in developing the new drug, Aprela, have raised questions about its potential. Some analysts and doctors question whether regulators will approve it, and Aprela's market potential could be limited by continued safety concerns about hormone-based drugs. The New (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=43 GlaxoSmithKline Plc (GSK), Eli Lilly & Co. and Pfizer Inc. (PFE) are among about half a dozen companies interested in buying a stake in Mustafa Nevzat Ilac Sanayii AS in a deal that may value the Turkish drugmaker at $1 billion, three people with knowledge of the situation said. The owners of Mustafa Nevzat, or MN Pharmaceuticals as the Istanbul-based company is known, have hired Bank of America Merrill Lynch to advise on the stake sale, said the people, who declined to be identified because (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=43 United States Patent: 8106069 |-| Title: Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors and pharmaceutical compositions comprising them |-| Inventors: Salom; Barbara (Milan, IT), D'Anello; Matteo (Milan, IT), Brasca; Maria Gabriella (Milan, IT), Giordano; Patrizia (Cuneo, IT), Martina; Katia (Novara, IT), Angelucci; Francesco (Milan, IT), Brookfield; Frederick Arthur (Oxon, GB), Trigg; William John (Oxon, GB), Boyd; Edward Andrew (Berkshire, GB), Larard; Jonathan Anthony (York, (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=43 EMERYVILLE, Calif.-(BUSINESS WIRE)- KineMed, Inc. (www.kinemed.com) today announced a non-exclusive research collaboration with Pfizer Inc. (NYSE:PFE - News) for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes. The collaboration will employ KineMed s Dynamic ProteomicsTM technology platform to map the impact of potential drug candidates on specific metabolic pathways. Diabetes is an increasingly challenging global healthcare problem and in the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=43 The fact that Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) has explicitly said that it has no plans to make large acquisitions any time soon has not stopped speculations about the company's next buyout. Indian website "VCCircle" reports that Teva is a contender to acquire Micro Labs Ltd. for almost $2 billion. While the amount is not on the scale of Teva's last three multibillion takeovers of Cephalon, ratiopharm, and Barr Pharmaceuticals, it is not a small amount either. (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=43 NEW YORK-(BUSINESS WIRE)- Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved INLYTA (axitinib), a kinase inhibitor, for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. The approval is based on data from the Phase 3 AXIS trial, which demonstrated that INLYTA significantly extended progression free survival (PFS) [HR=0.67, 0.54-0.81, P1.5 x ULN and should be used with caution when treating (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 The main pathological consequence of free radical exposure is DNA damage, which is known to induce cell transformation and to facilitate important mutations in cancer progression. It is a matter of intense discussion whether the drug-induced production of free radicals limits the therapeutic efficacy of chemotherapeutics and enhances their toxicity or whether they may be enhanced to provoke cancer cell apoptosis. This paper reviews essential molecular processes to better understand the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 BACKGROUND: Postoperative atrial fibrillation (POAF) is a frequent complication of coronary artery bypass grafting (CABG) surgery. The objective of this study was to determine the impact of POAF on both short- and long-term mortality following isolated CABG. HYPOTHESIS: POAF is associated with a poorer short and long-term mortality following CABG. METHODS: We retrospectively analyzed the preoperative and operative data of 6728 consecutive patients undergoing a first isolated CABG. RESULTS: The (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 PURPOSE: To derive estimates of CYP1A2 abundance as a function of daily cigarette consumption and use these values to predict the clearances of CYP1A2 substrates in smokers. METHODS: Smoking-induced changes in hepatic CYP1A2 abundance were extrapolated from reported in vivo caffeine clearance data for sub-groups of a smoking population that were categorized according to their daily cigarette consumption. These (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 Nonstoichiometric channel hydrates are a class of crystalline hydrates that can incorporate a range of water levels as a function of temperature and relative humidity (RH). When a nonstoichiometric channel hydrate can dehydrate to yield a physically stable isostructural crystalline lattice, it may become challenging to accurately evaluate the thermodynamic stability relationship associated with a polymorphic system using traditional methods. This work demonstrates application of a (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 N-linked glycosylation can influence the biological activity and safety of an antibody as well as be a measure of the consistency of the production process. The released N-glycans is an important part of the development of a therapeutic antibody. The traditional method for N-glycan analysis requires complex and laborious sample preparation and lengthy analysis time. Two preparation steps with limited control are removal of the antibody backbone by ice-cold ethanol precipitation and water (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 Nucleoporin Tpr is a component of the nuclear pore complex (NPC) that localizes exclusively to intranuclear filaments. Tpr functions as a scaffolding element in the nuclear phase of the NPC and plays a role in mitotic spindle checkpoint signalling. Export of intron-containing mRNA in Mason Pfizer Monkey Virus is regulated by direct interaction of cellular proteins with the cis-acting Constitutive Transport Element (CTE). In mammalian cells, the transport of Gag/Pol-CTE reporter construct is (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 The preclinical safety studies required to support the development of inhaled drugs are generally the same as for other routes of administration. Repeat-dose toxicology studies should be conducted by inhalation to ensure the characterization of both the local (i.e., respiratory) and systemic toxicity, although some studies (e.g., reproductive) can be performed by utilizing alternative routes, when it is paramount to maximize systemic exposure. Respiratory tract changes in preclinical species (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=43 In clinical trials for antihypertensive drugs, a combination therapy trial and a monotherapy trial are often conducted simultaneously. In this situation, it can be a clinical concern to know the difference of the safety or efficacy of the new drug between the two therapies, in other words, to investigate the interaction between the therapy (monotherapy or combination therapy) and the treatment (test or control). However, because patients are often registered in either of these trials on the (…)